Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Issued: 2019-2025

Historic Shares Issued for Dianthus Therapeutics (DNTH) over the last 2 years, with Sep 2025 value amounting to $271.7 million.

  • Dianthus Therapeutics' Shares Issued rose 91680.07% to $271.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.9 million, marking a year-over-year increase of 50118.74%. This contributed to the annual value of $39.2 million for FY2024, which is 783900.00% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Shares Issued is $271.7 million, which was up 57,701.91% from $470,000 recorded in Q2 2025.
  • Dianthus Therapeutics' Shares Issued's 5-year high stood at $271.7 million during Q3 2025, with a 5-year trough of -$49,000 in Q3 2022.
  • Moreover, its 3-year median value for Shares Issued was $283,500 (2024), whereas its average is $38.9 million.
  • Over the last 5 years, Dianthus Therapeutics' Shares Issued had its largest YoY gain of 91,680.07% in 2025, and its largest YoY loss of 52.40% in 2025.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Shares Issued stood at -$49,000 in 2022, then spiked by 110.20% to $5,000 in 2023, then surged by 5,820.00% to $38.6 million in 2024, then spiked by 91,680.07% to $271.7 million in 2025.
  • Its Shares Issued was $271.7 million in Q3 2025, compared to $470,000 in Q2 2025 and $129,000 in Q1 2025.